CDKN2A and glioblastoma: To assess the impact of CDKN2A on glioblastoma cell viability, we performed MTT assays at different time points (0, 24, 48, 72 h) following CDKN2A knockdown (si-CDKN2A) or overexpression (CDKN2A).